DE MOTU CORDIS
Developing an epinephrine inhaler for use in anaphylaxis treatment.
De Motu Cordis’s mission is to improve emergency epinephrine delivery, when every second counts.
Needle-free
delivery
Rapid
administration
Everyday
storage
Simplicity
Designed for: Needle-free delivery · Rapid administration · Everyday storage · Simplicity
OUR TECHNOLOGY
Designed for simplicity.
Needle-free deliveryRapid administrationEveryday storageSimplicity
OUR TECHNOLOGY
Designed for everyday.
INSIDE THE DEVICE
Our technology
Single-Use, Pre-Loaded Dry Powder Inhaler
Protective capprotects device and primes drug powder release
Mouthpieceto inhale the drug powder
Capsule cartridgepre-loaded with capsule
Capsulecontaining inhalable drug formulation
➔
De Motu Cordis ProductAn epinephrine inhaler being developed to treat anaphylaxis
1Proprietary Dry
Powder Inhaler Device2Proprietary Inhalable
Epinephrine Formulation
BARRIERS TO CARE
Breaking Down Barriers to Care
BARRIER TO CARE
DESIGN FEATURES*
Patients may delay or avoid using auto-injector devices due to fear of needles
➔
Simple, needle-free delivery
Currently approved products may take 20–30 minutes to reach peak epinephrine levels
➔
Rapid epinephrine absorption
Common storage locations can exceed recommended storage conditions (20–25°C)
➔
Suitable for everyday storage
Auto-injector devices require replacement every 12–24 months due to expiry
➔
Extended shelf-life
*Based on current development objectives and subject to regulatory review and approval
“
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Placeholder — awaiting approved quote
DEVELOPMENT
Product development
2022
Proprietary epinephrine formulation
GMP pilot scale process established.
2022–2026
Early phase clinical studies
Supporting assessment of safety, tolerability, and early performance characteristics.
2026
Proprietary dry powder inhaler
Mature prototype design under characterisation.
